Could Repros Therapeutics Inc (RPRX) Go Up After Reaching 1 Year Low?

July 17, 2017 - By Nellie Frank

Investors sentiment decreased to 0.88 in Q4 2016. Its down 0.20, from 1.08 in 2016Q3. It dived, as 8 investors sold Repros Therapeutics Inc shares while 8 reduced holdings. 4 funds opened positions while 10 raised stakes. 6.56 million shares or 1.15% more from 6.48 million shares in 2016Q3 were reported.
Blackrock Fund has 0% invested in Repros Therapeutics Inc (NASDAQ:RPRX). Kcg Holdings owns 45,144 shares or 0% of their US portfolio. State Street Corporation reported 0% stake. California Pub Employees Retirement Systems invested 0% of its portfolio in Repros Therapeutics Inc (NASDAQ:RPRX). Vanguard Group Inc accumulated 882,436 shares. Manufacturers Life Insur The reported 1,321 shares. 39 were reported by Barclays Public Ltd Liability Corporation. Susquehanna Interest Llp reported 71,827 shares stake. Northern Tru has 72,672 shares. Benjamin F Edwards & invested 0% in Repros Therapeutics Inc (NASDAQ:RPRX). The New Jersey-based Blackrock Mngmt Ltd Limited Liability Company has invested 0% in Repros Therapeutics Inc (NASDAQ:RPRX). Blackrock Institutional Na accumulated 700,608 shares. Citigroup Inc has 0% invested in Repros Therapeutics Inc (NASDAQ:RPRX). Morgan Stanley holds 0% of its portfolio in Repros Therapeutics Inc (NASDAQ:RPRX) for 14,875 shares. Fmr Ltd Llc has 1.67 million shares.

The stock of Repros Therapeutics Inc (NASDAQ:RPRX) hit a new 52-week low and has $0.36 target or 3.00 % below today’s $0.37 share price. The 9 months bearish chart indicates high risk for the $10.88M company. The 1-year low was reported on Jul, 17 by If the $0.36 price target is reached, the company will be worth $326,400 less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

About 5.58M shares traded or 452.48% up from the average. Repros Therapeutics Inc (NASDAQ:RPRX) has declined 73.82% since July 17, 2016 and is downtrending. It has underperformed by 90.52% the S&P500.

Repros Therapeutics Inc (NASDAQ:RPRX) Ratings Coverage

Among 3 analysts covering Repros Therapeutics (NASDAQ:RPRX), 1 have Buy rating, 1 Sell and 1 Hold. Therefore 33% are positive. Repros Therapeutics had 5 analyst reports since August 20, 2015 according to SRatingsIntel. On Friday, October 30 the stock rating was downgraded by Ladenburg Thalmann to “Neutral”. The firm earned “Underperform” rating on Friday, October 30 by Bank of America. The stock has “Buy” rating by Ladenburg Thalmann on Wednesday, November 16. The stock of Repros Therapeutics Inc (NASDAQ:RPRX) earned “Hold” rating by Zacks on Thursday, August 20. The rating was downgraded by Brean Capital on Friday, October 30 to “Hold”.

More notable recent Repros Therapeutics Inc (NASDAQ:RPRX) news were published by: which released: “Form 8-K REPROS THERAPEUTICS INC. For: Jul 17” on July 17, 2017, also with their article: “BUZZ-US STOCKS ON THE MOVE-Snap, Repros, Sprint, BlackRock” published on July 17, 2017, published: “Repros Names Larry Dillaha, MD, its Permanent President and CEO” on April 10, 2017. More interesting news about Repros Therapeutics Inc (NASDAQ:RPRX) were released by: and their article: “Repros Announces Proposed Public Offering Of Common Stock And Warrants To …” published on May 17, 2017 as well as‘s news article titled: “Repros Announces the Issuance of New US Patent Relating to Treatment Using Off …” with publication date: April 17, 2017.

Repros Therapeutics, Inc. is a biopharmaceutical firm focused on the development of new drugs to treat hormonal and reproductive system disorders. The company has market cap of $10.88 million. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. It currently has negative earnings. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.